The Food and Drug Administration granted an Emergency Use Authorization for the Johnson & Johnson COVID-19 vaccine.
The TeamHealth Emerging Infectious Disease Task Force (EIDT) analyzed Johnson & Johnson vaccine trial data and reached the following, unanimous conclusion:
The EIDT recommends vaccination with the Janssen Ad26.COV2.S vaccine (Janssen COVID-19 Vaccine) for all adults 18 years of age and above in every racial and ethnic demographic regardless of COVID-19 risk factors, prior COVID-19 infection, or other underlying health conditions, unless there are existing contraindications to receiving any vaccine. The EIDT would not recommend this vaccine for pregnant or lactating individuals due to a current paucity of safety data regarding both the vaccine and the Ad26 viral vector platform in this population, particularly when the Pfizer and Moderna vaccines are available for these individuals at this time.
The EIDT is committed to synthesizing and offering you the most up-to-date information related to COVID-19. Download the full EIDT Johnson & Johnson COVID-19 vaccine analysis below.